Abstract A092: Pathologic complete response and downstaging after neoadjuvant immunotherapy in head and neck squamous cell carcinoma
Following the KEYNOTE-689 presentation in 2025, neoadjuvant immunotherapy has become an integral component of perioperative treatment for head and neck squamous cell carcinoma (HNSCC). As pathologic response is increasingly used to assess treatment efficacy, we evaluated rates of pathologic complete response (pCR...